Introduction
============

Irritable bowel syndrome (IBS) is a common non-organic bowel disorder, which is associated with chronic abdominal pain, bloating, discomfort, and irregular bowel movement.[@b1-jnm-24-628] The patho-physiology of IBS is poorly understood; however, several possible mechanisms have been proposed including altered gastrointestinal (GI) microbiota, infectious gastroenteritis, visceral hypersensitivity, dysregulation of gut-brain axis, chronic stress, and genetic factors.[@b1-jnm-24-628]--[@b3-jnm-24-628] Recent studies reported that mild inflammation exists at least in a subgroup of patients with IBS, which is associated with gut dysfunction, increased permeability of intestinal epithelial cells (IECs), and altered profile of proinflammatory and anti-inflammatory cytokines.[@b1-jnm-24-628],[@b4-jnm-24-628] However, the underlying pathophysiology of low-grade inflammation among patients with IBS remains unknown.

The low-grade inflammation among patients with IBS might be due to aberrant stimulation of innate and adaptive immune responses.[@b5-jnm-24-628],[@b6-jnm-24-628] Dysregulated mucosal and systemic immune responses have been shown among patients with IBS.[@b7-jnm-24-628] Pattern-recognition receptors, like toll-like receptors (TLRs), are important components of the innate immune system and play a central role in mucosal immune response among patients with IBS.[@b8-jnm-24-628] TLRs recognize conserved pathogen-associated molecular patterns allowing the initiation of innate immune response via triggering the expression of cytokines and chemokines.[@b4-jnm-24-628]

Almost all TLRs are expressed on the intestinal epithelial cells in the small intestine as well as in the colon.[@b9-jnm-24-628] The interaction between TLRs and gut microbiota contributes to the maintenance of the integrity of the intestinal epithelial barrier and homeostasis.[@b10-jnm-24-628],[@b11-jnm-24-628] However, qualitative or quantitative alterations in gut microbiota play a pivotal role in perpetuating the altered host immune response. One study from our center showed that Gram-negative and segmented filamentous bacteria were higher, while Gram-positive bacteria were comparable among patients with IBS than controls.[@b3-jnm-24-628] TLRs recognize a wide range of microbial ligands such as poly-peptides of Gram-positive bacteria (TLR-2), lipopolysaccharides of Gram-negative bacteria (TLR-4) and flagellum proteins of filamentous bacteria (TLR-5).[@b8-jnm-24-628] Binding of these ligands to receptors results in activation of a downstream cascade of cytokines and chemokines production leading to intestinal inflammation.[@b12-jnm-24-628]

In addition to innate immunity, TLRs also help in the activation of adaptive immune response. Cross talk between gut microbiota and IECs induces the differentiation of T helper (Th) cells into Th1 and Th2 cells.[@b13-jnm-24-628] Previous studies reported that TLR-2 was associated with Th2 cytokines production and TLR-4 with Th1 cytokine production.[@b14-jnm-24-628],[@b15-jnm-24-628] Recently, a study showed that TLR-2 ligands induce the production of IL-10, while TLR-4 ligands induce the production of proinflammatory cytokine IL-12 (p70) and reduce IL-10 in the dendritic cells.[@b14-jnm-24-628] Published data indicate that stimulation of TLR-5 with flagellin protein induces the expression of chemokine C-X-C motif chemokine ligand 11 (CXCL-11), which plays an important role in intestinal inflammation.[@b16-jnm-24-628] The receptor of CXCL-11 is expressed by Th1 cells (C-X-C motif chemokine receptor 3 \[CXCR-3\]); binding of CXCL-11 with CXCR-3 receptor stimulates the Th1 cells to release the proinflammatory cytokines like IL-6.[@b16-jnm-24-628],[@b17-jnm-24-628] Recently, one study has shown that IL-6 is an important mediator of gut dysfunction among patients with inflammatory bowel disease (IBD).[@b17-jnm-24-628],[@b18-jnm-24-628] Moreover, CXCR-3 inhibition reduces the expression of IL-6 among patients with IBD.[@b17-jnm-24-628] To the best of our knowledge, mRNA expression of CXCL-11 and its receptor CXCR-3 has not been studied among patients with IBS so far. Thus, based on the above evidence, we hypothesized that TLR mediated cytokines and chemokines in relation to altered gut microbi-ota or pathogen-derived products may be involved in pathogenesis of intestinal inflammation. Scanty data have been reported on this issue and most of the studies are performed in peripheral blood.[@b12-jnm-24-628],[@b19-jnm-24-628] Therefore, this study was designed with the following objectives; to study (1) expression of TLR-2, 4, and 5 in colonic biopsies among patients with IBS and controls, (2) expression of proinflammatory (IL-6, CXCL-11, and CXCR-3) and anti-inflammatory cytokines (IL-10) in colonic biopsies among patients with IBS and controls, and (3) relationship between mRNA levels of TLRs, cytokines, and chemokines with the altered fecal microbiota published previously from our center.[@b3-jnm-24-628]

Materials and Methods
=====================

Study Subjects
--------------

Patients with IBS attending the Gastroenterology out-patient clinic of a super specialty multi-level university hospital from northern India and fulfilling the Rome III criteria were recruited. Patients with IBS were classified into 3 subtypes *viz* diarrhea-predominant (IBS-D), constipation-predominant (IBS-C), and un-subtyped (IBS-U) using Rome III criteria. Subjects without any functional GI disorder by Rome III criteria undergoing flexible sigmoidoscopy for per rectal bleeding that did not reveal any abnormality (except piles) were included as controls. Patients and controls subjects were excluded if they had organic or metabolic diseases or those who received antibiotics, probiotics, prokinetics, or antispasmodic drugs within the previous 4 weeks. Each patient was subjected to clinical investigations such as stool microscopy and occult blood testing, hematology, thyroid function test, and proctosigmoidoscopy. Written informed consent was obtained from all the participants. The study protocol was approved by the Institutional Ethical Committee (No. 2012-132-EMP-64).

Assessment of Clinical Symptoms
-------------------------------

Patients with IBS and controls were interviewed using a locally translated and validated Rome III diagnostic questionnaire[@b20-jnm-24-628] to record demographic and clinical symptoms of IBS such as abdominal pain or discomfort, bloating, straining, the passage of mucus, altered bowel habits, and type of stool (using Bristol stool chart with pictorial presentation and descriptors).

Collection and Processing of Biopsy Tissues
-------------------------------------------

Patients with IBS and controls were subjected to proctosigmoidoscopy. During a sigmoidoscopy, 3 biopsies from the sigmoid colon were collected in Trizol solution (Invitrogen, Carlsbad, CA, USA). All biopsy samples were snap frozen in liquid nitrogen and stored at −80°C for RNA extraction. Additionally, 3 biopsies were collected in 10% formalin for immunohistochemistry.

Quantitative Real-time Polymerase Chain Reaction
------------------------------------------------

Total RNA from colonic tissues was extracted using Qiagen RNeasy kit (Qiagen Inc, Valencia, CA, USA) according to the manufacturer's protocol. Quality and quantity of RNA were confirmed by NanoDrop ND-2000 Spectrophotometer (NanoDrop products, Wilmington, DE, USA). RNA (100 ng) was reverse transcribed into cDNA using cDNA synthesis kit (High-Capacity cDNA Reverse Transcription Kits; Applied Biosystems, Carlsbad, CA, USA), according to manufacturer's instructions. Quantitative real-time polymerase chain reaction (qRT-PCR) was performed in a reaction volume of 25 μL, containing 12.5 μL of SYBR Green master mixture (Applied Biosystems, Carlsbad, USA), 0.25 μL of 10 pmol of forward and reverse primers and 2 μL of cDNA. All reactions were run in duplicate in Corbett Research 6000 Q-PCR instrument (Rotor gene 6000 software, Sydney, Australia). Primer sequences of target genes are listed in [Table 1](#t1-jnm-24-628){ref-type="table"}.[@b21-jnm-24-628]--[@b27-jnm-24-628] Beta-actin was used as a housekeeping gene to normalize the reaction volume of RNA. Thermal cycling conditions for target genes were as follows: initially samples were heated at 95°C for 10 minutes to activate Am-pliTaq Gold DNA polymerase followed by 40 cycles of amplification via denaturation at 95°C for 15 seconds, annealing at optimal temperature ([Table 2](#t2-jnm-24-628){ref-type="table"}) for 30 seconds, extension at 72°C for 30 seconds. Melting curve analysis was also run with increasing temperature from 60°C to 95°C (at a regular increment of 0.5°C for 5 seconds) to assure that fluorescence is coming from our desired amplicon and not from primer dimer or non-specific PCR amplified products. In addition, quality of qRT-PCR products was confirmed by subjecting to 2% agarose gel electrophoresis. Replacing template RNA with diethyl pyrocarbonate-water (Sigma, St. Louis, MO, USA) was used as negative control for qRT-PCR. Data were normalized with housekeeping β-actin gene and relative fold change for target gene was presented using 2^−ΔCt^ comparative Ct method.

Immunohistochemistry
--------------------

Colonic biopsies were immediately fixed in formalin and embedded in paraffin as per standard protocol.[@b28-jnm-24-628] Three to five micra sections were cut using microtome (Reichert-Jung 2030 Biocut; Leica, Heidelberg, Germany) and mounted onto clean poly L-lysine coated glass slides. The slides were dried for 4--6 hours at 60°C, de-paraffinized in xylene and rehydrated using decreasing grades of alcohol series. Sodium citrate buffer (1.5 M, pH 6.0) was used for antigen retrieval. Slides were kept in a microoven at 95°C for 15 minutes each for 2 times and left to cool in the antigen retrieval buffer. Slides were washed 3 times with phosphate-buffered saline (PBS; pH 7.4). Sections were incubated with 3% hydrogen peroxide in methanol and kept in dark for 30 minutes to block the endogenous peroxidase activity. The sections were washed 3 times with PBS. Non-specific antigens were blocked with 5% sheep serum at room temperature for 1 hour. Thereafter, sections were incubated with the mouse monoclonal anti-TLR-4 antibody (1:100 dilution; Abcam, Milton, Cambridge, UK) and rabbit polyclonal anti-TLR-5 (1:50 dilution; Abcam, Cambridge, UK) at room temperature for 1 hour in a humidified chamber. The primary antibody was replaced with PBS for negative controls. Slides were washed 3 times with PBS. Subsequently, sections were incubated with the biotinylated secondary antibody (Novacastra; Leica Biosystems New-castle Ltd, Newcastle Upon Tyne, UK) for 45 minutes at room temperature. After that, sections were incubated with 3, 3′-diamino-benzidine (DAKO, Glostrup, Denmark) to visualize the reaction products and counterstained with hematoxylin. The sections were washed with water, dehydrated with several grades of alcohols (30%, 50%, 70%, and 100%) and xylene. Finally, sections were mounted with mixture of distyrene, plasticizer, and xylene (DPX) mountant. Three images for each slide having consistent staining were taken using Nikon Eclipse Ci H600L (Nikon, Tokyo, Japan) microscope at 10× magnification.

Analysis of Gut Microbiota
--------------------------

Analysis of fecal microbiota was performed in the same group of IBS patients as described previously.[@b3-jnm-24-628] Fecal DNA extraction and real-time PCR for amplification of 16S rRNA gene of target bacteria were reported previously.[@b3-jnm-24-628] In this study, we examined the correlation between the copy number of target bacteria with mRNA level of TLRs, cytokines, and chemokines among patients with IBS.

Statistical Methods
-------------------

The mRNA levels of TLRs, cytokines, and chemokines are presented as median and range. Chi-square and Mann-Whitney *U* tests were used for categorical and continuous data, respectively. The comparative mean Ct method (2^−ΔCt^) is used to express the fold change of mRNA level of target gene. Mann-Whitney *U* test was used to compare the mRNA expression of target gene between patients with IBS and controls. The non-parametric Kruskal-Wallis H test with post hoc Bonferroni test was applied for comparison of more than 2 groups. Spearman correlation was used to determine the relationship between mRNA level of TLRs, cytokines, and chemokines with clinical symptoms and copy number of target bacteria. ImageJ software version 1.46r (Wayne Rasband, National Institutes of Health, Bethesda, MD, USA; <http://rsb.info.nih.gov/ij/> <http://rsb.info.nih.gov/ij/>) was used for quantitative analysis of IHC image for TLR-4 and TLR-5.[@b29-jnm-24-628] An average value of three fields for each image was considered as percentage staining of positive cells. *P*-values less than 0.05 were considered as significant. All data were analyzed with Graph Prism version 5.0 (GraphPad Software Inc, La Jolla, CA, USA) and SPSS version 15.0 (IBM Corp, Armonk, NY, USA).

Results
=======

Demographic and Clinical Characteristics of Patients With Irritable Bowel Syndrome and Controls
-----------------------------------------------------------------------------------------------

A total of 47 patients with IBS and 25 controls comparable in age (median 34 years \[19--68\] vs 40 \[20--68\], *P* = 0.271) and gender (39/47 \[83%\] vs 22/25 \[88%\] male, *P* = 0.573) were included. Patients with IBS were sub-typed into IBS-D (n = 20), IBS-C (n = 20), and IBS-U (n = 7) using the Rome III criteria. Clinical characteristics of the patients with IBS and controls are presented in [Table 2](#t2-jnm-24-628){ref-type="table"}.

Expression of Messenger RNA Level of Toll-like Receptors Among Patients With Irritable Bowel Syndrome and Controls
------------------------------------------------------------------------------------------------------------------

There was no difference in mRNA level of TLR-2 among patients with IBS and controls (*P* = 0.090, [Table 3](#t3-jnm-24-628){ref-type="table"}). The expression of TLR-4 and TLR-5 was 1.2-folds and 6-folds higher among patients with IBS than controls (*P* = 0.013 and *P* \< 0.001, respectively) ([Table 3](#t3-jnm-24-628){ref-type="table"}). Among different subtypes of IBS, the mRNA levels of TLR-4 and TLR-5 were 1.3-folds and 8-folds higher in patients with IBS-D than controls ([Table 4](#t4-jnm-24-628){ref-type="table"} and [Fig.1B and 1C](#f1-jnm-24-628){ref-type="fig"}). Moreover, the expression of TLR-4 and TLR-5 was 6-folds and 2.7-folds higher among patients with IBS-D than IBS-C (*P* = 0.013 and *P* = 0.040, respectively). A 2-folds higher expression of TLR-5 was found in patients with IBS-C than controls (*P* = 0.021), while the TLR-4 level was comparable in IBS-C patients as compared to controls (*P* = 0.239) ([Fig. 1](#f1-jnm-24-628){ref-type="fig"}).

The Protein Level of Toll-like Receptors 4 and 5 Among Patients With Irritable Bowel Syndrome and Controls
----------------------------------------------------------------------------------------------------------

The mRNA levels of TLR-4 and TLR-5 were further confirmed at the protein level in colonic biopsies using immunohisto-chemistry. Protein expressions of TLR-4 and TLR-5 were more intense in crypt and luminal surface among patients with IBS than controls ([Fig. 2A and 2B](#f2-jnm-24-628){ref-type="fig"}). Moreover, TLR-4 expression was more prominent and 4.2-folds higher in patients with IBS-D than controls ([Fig. 2C](#f2-jnm-24-628){ref-type="fig"}). Likewise, TLR-5 expression was 4.1-folds higher in IBS-C and 6.6-folds in IBS-D patients than controls ([Fig. 2D](#f2-jnm-24-628){ref-type="fig"}). No positive staining was seen in the negative controls ([Fig. 2A and 2B](#f2-jnm-24-628){ref-type="fig"}).

The Messenger RNA Levels of Cytokines (Interleukin-6 and Interleukin-10), Chemokine C-X-C Motif Chemokine Ligand 11 and Its Receptor (C-X-C Motif Chemokine Receptor 3)
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------

The mRNA level of IL-6 was 2.2-folds higher among patients with IBS than controls (*P* = 0.003). Likewise, CXCL-11 and its receptor CXCR-3 were 10-folds and 1.5-folds higher among patients with IBS than controls (*P* \< 0.001 and *P* \< 0.001, respectively). Among the different subtypes of IBS, mRNA level of IL-6 was 2-folds higher in patients with IBS-D than controls (*P* = 0.002) ([Table 4](#t4-jnm-24-628){ref-type="table"}). Likewise, CXCL-11 and CXCR-3 were up-regulated in IBS-D patients as compared to controls ([Fig. 3C and 3D](#f3-jnm-24-628){ref-type="fig"}). Moreover, mRNA level of CXCR-3 was 4-folds higher among patients with IBS-D than IBS-C ([Table 4](#t4-jnm-24-628){ref-type="table"}).

There was no difference in mRNA level of an anti-inflammatory cytokine (IL-10) in patients with IBS than controls (*P* = 0.546). Expression of IL-10 was down-regulated among patients with IBS-D than IBS-C and controls ([Fig. 3B](#f3-jnm-24-628){ref-type="fig"}). The mRNA levels of TLRs, cytokines, and chemokines among different subtypes of IBS and controls are presented in [Table 4](#t4-jnm-24-628){ref-type="table"}.

Correlation Between Messenger RNA Level of Toll-like Receptors, Cytokines, and Chemokines
-----------------------------------------------------------------------------------------

There was a trend towards a correlation between mRNA levels of TLR-4 and TLR-5 (Spearman correlation coefficient \[*r*\] = 0.284, *P* = 0.053) among patients with IBS ([Fig. 4A](#f4-jnm-24-628){ref-type="fig"}). A positive correlation was seen between mRNA level of TLR-4 with IL-6 (*r* = 0.296, *P* = 0.043) ([Fig. 4B](#f4-jnm-24-628){ref-type="fig"}). Moreover, mRNA expression of CXCR-3 showed correlation with CXCL-11 and IL-6 (*r* = 0.290, *P* = 0.047 and *r* = 0.423, *P* = 0.003, respectively) ([Fig. 4C and 4D](#f4-jnm-24-628){ref-type="fig"}).

Association Between Symptoms of Irritable Bowel Syndrome and Messenger RNA Levels of Toll-like Receptors, Cytokines, and Chemokines
-----------------------------------------------------------------------------------------------------------------------------------

The expressions of TLR-4, TLR-5 and CXCR-3 were higher among IBS patients with loose watery stool with frequency more than 3 times per day than those without ([Table 5](#t5-jnm-24-628){ref-type="table"}). Moreover, the mRNA level of IL-10 was lower in patients who had more frequent and loose stool at the onset of pain, stool frequency more than 3 times per day than those without ([Table 5](#t5-jnm-24-628){ref-type="table"}). In contrast, patients presenting with hard or lumpy stool had a reduced level of TLR-4 and CXCR-3 and increased level of IL-10 than those without ([Table 5](#t5-jnm-24-628){ref-type="table"}).

Correlation Between Messenger RNA Levels of Toll-like Receptors, Cytokines, and Chemokines With Duration of Symptoms and Weekly Stool Frequency
-----------------------------------------------------------------------------------------------------------------------------------------------

The mRNA expression of TLR-4 and CXCR-3 showed correlation with weekly stool frequency in IBS patients (*r* = 0.349, *P* = 0.016 and *r* = 0.399, *P* = 0.005, respectively) ([Fig. 5A and 5C](#f5-jnm-24-628){ref-type="fig"}). Moreover, expression of IL-10 inversely correlated with stool frequency (*r*, −0.435; *P* = 0.002) ([Fig. 5B](#f5-jnm-24-628){ref-type="fig"}). However, there was no correlation between duration of symptoms and mRNA expression of TLRs, cytokines, and chemokines ([Table 6](#t6-jnm-24-628){ref-type="table"}).

Correlation Between the Copy Number of Altered Fecal Microbiota and Messenger RNA Levels of Toll-like Receptors, Cytokines, and Chemokines
------------------------------------------------------------------------------------------------------------------------------------------

The number of copies of *Lactobacillus* and *Bifidobacterium* species correlated with IL-10 level among patients with IBS-C (*r* = 0.453, *P* = 0.045 and *r* = 0.554, *P* = 0.011, respectively). Moreover, number of copies of Gram-positive and Gram-negative bacteria showed correlation with CXCL-11 (*r* = 0.482, *P* = 0.031 and *r* = 0.561, *P* = 0.010, respectively) among patients with IBS-D.

Discussion
==========

Recent studies show that low-grade inflammation in response to altered gut microbiota may be involved in the pathophysiology of IBS. The present study suggests that TLR-mediated cytokines and chemokines may play important role in the pathophysiology of mild inflammation at least in a subgroup of IBS patients with following evidence: (1) up-regulation of TLR-4 and TLR-5 among patients with IBS, particularly IBS-D, than controls, (2) expression of pro-inflammatory cytokine (IL-6) was higher, while anti-inflammatory cytokine (IL-10) lower in IBS-D patients than controls, (3) chemokines CXCL-11 and its receptor CXCR-3 were higher in IBS-D patients than controls, (4) mRNA level of TLR-4 showed correlation with IL-6; CXCR-3 showed correlation with CXCL-11 and IL-6 among patients with IBS, and (5) mRNA expression of TLR-4 and CXCR-3 showed correlation with stool frequency per week, while IL-10 inversely correlated with stool frequency in IBS patients.

IECs act as a barrier between luminal microbiota and gut-associated immune cells.[@b30-jnm-24-628] In vitro, in vivo, and several intestinal epithelial cell lines express TLRs.[@b31-jnm-24-628] TLRs play a pivotal role in maintaining the gut homeostasis through secretion of pro-inflammatory cytokines and chemokines.[@b32-jnm-24-628] Altered expressions of TLRs in response to dysbiosis have been reported in several GI diseases.[@b12-jnm-24-628] Moreover, one study from our center showed that Gram-negative bacteria (particularly *Pseudomonas aeruginosa* and *Bacteroides thetaiotamicron*) and segmented filamentous bacteria were increased, while Gram-positive bacteria were comparable among patients with IBS-D than controls.[@b3-jnm-24-628] TLR-4 and TLR-5 show activity against the ligands of Gram-negative (lipopolysaccharides) and segmented filamentous bacteria (flagellin protein).[@b4-jnm-24-628] Therefore, we studied the role of TLR-4 and TLR-5 in the pathogenesis of low-grade inflammation among patients with IBS.

In the present study, mRNA level of TLR-2 was comparable among patients with IBS and controls, which is in accordance with a previous study.[@b4-jnm-24-628] We found mRNA and protein levels of TLR-4 and TLR-5 were up-regulated among patients with IBS, particularly IBS-D, than controls supporting the hypothesis that mild inflammation occurs in a subtype of IBS. Our results corroborated with a higher level of TLR-4 and TLR-5 reported in patients with IBS.[@b4-jnm-24-628] Moreover, up-regulation of TLR-4 was seen in patients with Crohn's disease and ulcerative colitis.[@b31-jnm-24-628] A study showed that rats with stress-induced IBS had higher mRNA levels of TLR-4 and TLR-5 in colonic mucosa than controls.[@b33-jnm-24-628] Likewise, another study reported that the expression of TLR-4 and TLR-5 was 4-folds and 1.7-folds higher among female IBS patients as compared to controls.[@b4-jnm-24-628] Results of immunohistochemistry showed that expression of TLR-4 and TLR-5 was more prominent in the colonic crypt as well as in intestinal epithelial cells, which is in accordance with a previous study.[@b4-jnm-24-628] Conversely, Belmonte and his colleagues[@b8-jnm-24-628] showed that mRNA and protein levels of TLR-4 in colonic mucosa were comparable in IBS-D, while higher in IBS-M patients as compared to controls. This may be due to heterogeneity in IBS patients and control population as well as the site of sample collection.[@b8-jnm-24-628]

TLRs play an important role in the activation of cytokine and chemokine release and its higher levels have been reported in patients with IBD and IBS.[@b4-jnm-24-628],[@b12-jnm-24-628],[@b34-jnm-24-628]--[@b36-jnm-24-628] Recently, a study showed a higher level of IL-6 in the peripheral blood of IBS patients on stimulation with TLR-ligands compared to controls, which is in accordance with the present study.[@b12-jnm-24-628] Though several studies reported IL-6 expression in peripheral blood of patients with IBS, its level in colonic biopsies is scanty. IL-6 is an important pro-inflammatory cytokine and its alteration may lead to variation in the level of GI mucosal inflammation and hence, the severity of IBS symptoms.[@b37-jnm-24-628]--[@b39-jnm-24-628] In addition, the mRNA level of TLR-4 showed a positive correlation with TLR-5 and IL-6 in the present study. These findings indicate that TLRs act synergistically to stimulate the innate immune response and subsequent release of pro-inflammatory cytokines and chemokines in response to gut dysbiosis.

We found that the mRNA level of an anti-inflammatory cytokine (IL-10) was reduced in patients with IBS-D than controls. This finding corroborated with the results of previous studies showing a reduced level of IL-10 in the sigmoid colon in female IBS patients than controls.[@b40-jnm-24-628] Recently, another study showed reduced expression of IL-10 in colonic biopsies among patients with IBS-D than controls.[@b41-jnm-24-628] The key role of IL-10 is to inhibit the synthesis of pro-inflammatory cytokines. But, its reduced level in the intestine favors synthesis and secretion of inflammatory cytokines and chemokines that are in agreement with the present findings. At the genotypic level, van der Veek et al[@b42-jnm-24-628] showed that the low producer IL-10 genotype was more frequent among patients with IBS than controls. Thus, reduced level of IL-10 suggests that patients with IBS are more susceptible to external stimuli (gut pathogens and antigens) causing inflammation as compared to controls.

The role of chemokines against luminal antigens in the pathogenesis of IBS is unknown. Published data showed that exposure of TLR-5 ligands led to higher levels of CXCL-11 in serum as well as in biopsies among patients with IBD.[@b16-jnm-24-628] Moreover, the CXCR-3/ CXCL-11 pathway is involved in response to bacterial flagellin in several intestinal immune mediated disorders like IBD.[@b16-jnm-24-628] CXCR-3 is mainly expressed by Th1 cells.[@b43-jnm-24-628] Therefore, binding of CXCL-11 to CXCR-3 may stimulate Th-1 cells to release IL-6.[@b16-jnm-24-628] In the present study, we also found a positive correlation between mRNA levels of CXCR-3 and IL-6. In support of this, a study showed that CXCR-3 inhibition reduced the expression of IL-6 in patients with IBD.[@b17-jnm-24-628],[@b44-jnm-24-628] Alterations in the level of cytokines and chemokines among IBS patients may be due to increased permeability of IECs resulting in translocation of colonic bacteria to the underlying submucosa.[@b4-jnm-24-628] In addition, leaky gut epithelium and down-regulation of tight junction proteins such as occludin have been reported in IBS patients.[@b45-jnm-24-628] These data suggest that CXCR-3/CXCL-11 play a substantial role in the pathogenesis of low-grade inflammation, at least in a subgroup of patients with IBS.

We found IBS patients with more frequent and loose stool at the onset of pain had increased level of TLR-4 and decreased level of IL-10 than those without. Moreover, a positive correlation was found between mRNA levels of TLR-4 and CXCR-3 with weekly stool frequency in IBS patients. In contrast, a previous study,[@b8-jnm-24-628] failed to show a correlation between mRNA levels of TLRs and duration of symptoms. Recent studies reported that higher level of cytokines resulted in visceral hyperalgesia[@b12-jnm-24-628],[@b46-jnm-24-628] and stress response, which might affect GI motility in IBS patients.[@b47-jnm-24-628] Moreover, patients with IBS express hypersensitivity to pain.[@b12-jnm-24-628]

We wish to emphasize that alteration in gut microbiota may have a crucial role in the pathogenesis of low-grade inflammation in patients with IBS. A positive correlation was found between the copy number of *Lactobacillus* and *Bifidobacterium* species and mRNA levels of IL-10 among patients with IBS-C. Recent studies have shown that the number of copies of *Lactobacillus* and *Bifidobacterium* was reduced in IBS patients than controls.[@b3-jnm-24-628],[@b48-jnm-24-628],[@b49-jnm-24-628] A study has shown that administration of *Lactobacillus rhamnosus* GR-1 and *Lactobacillus reuteri* RC-14 enhances the population of Treg cells in patients with IBS.[@b50-jnm-24-628] Moreover, administration of *Bifidobacterium infantis* 35624 increased the level of anti-inflammatory cytokines and normalized the ratio of IL-10/IL-12.[@b51-jnm-24-628] Thus, the reduction in a number of *Lactobacillus* and *Bifidobacterium* may be associated with low-grade inflammation. In the present study, Gram-positive and Gram-negative bacteria showed a correlation with CXCL-11 among patients with IBS-D. In support of this, higher copy number of Gram-negative bacteria particularly *Bacteroides* species and *P. aeruginosa* has been reported among patients with IBS-D than controls.[@b3-jnm-24-628] To the best of our knowledge, this is the first study evaluating the correlation between altered fecal microbiota and mRNA levels of immune mediators among different subtypes of IBS patients. Manipulation of gut microbiota using probiotic, antibiotics, and fecal transplantation may be useful in IBS and IBD patients, further proving the role of dysbiosis and inflammation in the pathogenesis of a subset of patients.[@b52-jnm-24-628]--[@b54-jnm-24-628]

In conclusion, up-regulation of TLR-4 and TLR-5 suggest that the innate immune system may play an important role in the pathophysiology of IBS. The up-regulation of pro-inflammatory cytokines (IL-6, CXCL-11, and CXCR-3) and down-regulation of the anti-inflammatory cytokine (IL-10) in patients with IBS-D than controls suggest the presence of low-grade intestinal inflammation in a subgroup of IBS patients. This study shows a relationship between the mRNA of TLRs, cytokines, chemokines, and copy number of altered fecal microbiota. These results highlight the complex interactions between the host immune system and gut microbiota leading to the pathogenesis of intestinal inflammation. Thus, alteration in normal microbial flora seems to contribute to dysregulated immune response among patients with IBS.
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![Relative expression of toll-like receptors (TLRs) among different subtypes of patients with irritable bowel syndrome (IBS) and controls. (A) TLR-2, (B) TLR-4, and (C) TLR-5. Mann-Whitney *U* test was used for pair-wise comparison of mRNA level of TLRs (2, 4, and 5) among different subtypes of IBS and controls. Post hoc Bonferroni test was applied for multiple comparisons. \**P*-values \< 0.05 were considered as significant. \*\*Bonferroni corrected *P*-values \< 0.017 were considered as significant for subgroup analysis. IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS.](jnm-24-628f1){#f1-jnm-24-628}

![Immunohistochemical analysis of Toll-like receptors (TLRs) 4 and 5 among different subtypes of patients with irritable bowel syndrome (IBS) and controls. Figures (A) and (B) show protein expression of TLR-4 and TLR-5 in colonic biopsies among different subtypes of IBS patients and controls. Protein expression of TLR-4 (C) and TLR-5 (D) was quantified using ImageJ software plugins. Figures (C) and (D) show the percentage contribution of positive cells for TLR-4 and TLR-5. IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS.](jnm-24-628f2){#f2-jnm-24-628}

![Comparison of cytokines and chemokines among different subtypes of patients with irritable bowel syndrome (IBS) and controls. (A) IL-6, (B) IL-10, (C) C-X-C motif chemokine ligand 11 (CXCL-11), and (D) C-X-C motif chemokine receptor 3 (CXCR-3). Mann-Whitney *U* test was used for pair-wise comparison of mRNA levels of cytokines (IL-6 and IL-10) and chemokines (CXCL-11 and CXCR-3) among different subtypes of irritable bowel syndrome (IBS) and controls. Post hoc Bonferroni test was applied for multiple comparisons. \**P*-values \< 0.05 were considered as significant. \*\*Bonferroni corrected *P*-values \< 0.017 were considered as significant for subgroup analysis. IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS.](jnm-24-628f3){#f3-jnm-24-628}

![Correlation among toll-like receptors (TLRs), cytokines, and chemokines using nonparametric Spearman correlation. (A) Between TLR-4 and TLR-5, (B) TLR-4 and IL-6, (C) C-X-C motif chemokine receptor 3 (CXCR-3) and C-X-C motif chemokine ligand 11 (CXCL-11), and (D) CXCR-3 and IL-6.](jnm-24-628f4){#f4-jnm-24-628}

![Spearman correlation of toll-like receptor-4 (TLR-4), IL-10, and C-X-C motif chemokine receptor 3 (CXCR-3) with stool frequency per week. Stool frequency per week showed a correlation with TLR-4 and CXCR-3 (A, B), while negative correlation with IL-10 (C).](jnm-24-628f5){#f5-jnm-24-628}

###### 

Primer Sequences for Messenger RNA Expression of Target Genes

  -----------------------------------------------------------------------------------------------------------
  Target gene   Primer sequence (5′-3′)         Product size (bp)   Annealing temp (°C)   Ref
  ------------- ------------------------------- ------------------- --------------------- -------------------
  TLR-2         FP: CTGCAAGCTGCGGAAGATAAT\      107                 56                    [@b21-jnm-24-628]
                RP: AGGACTTTATCGCAGCTCTCAGA                                               

  TLR-4         FP: TGCAATGGATCAAGGACCAGAGGC\   449                 68                    [@b22-jnm-24-628]
                RP: GTGCTGGGACACCACAACAATCACC                                             

  TLR-5         FP: GCATTAAGGGGACTAAGCCTC\      350                 58.6                  [@b23-jnm-24-628]
                RP: AAAAGGGAGAACTTTAGGGACT                                                

  IL-6          FP: GTGAAAGCAGCAAAGAGGCA\       276                 58                    [@b24-jnm-24-628]
                RP:TTGGGTCAGGGGTGGTTATT                                                   

  IL-10         FP: AGTCGCCACCCTGATGTCTC\       223                 58.2                  [@b25-jnm-24-628]
                RP: CCTGGGGGAGAACCTGAAG                                                   

  CXCL-11       FP: CCTTGGCTGTGATATTGTGTGC\     101                 62.7                  [@b26-jnm-24-628]
                RP: CACTTTCACTGCTTTTACCCCAG                                               

  CXCR-3        FP: AGGTGCCCTCTTCAACATCAA\      101                 63.7                  [@b26-jnm-24-628]
                RP: GGTAGAGCTGGGTGGCATGA                                                  

  β-actin       FP: CATGCCATCCTGCGTCTGGACC\     400                 58                    [@b27-jnm-24-628]
                RP:ACATGGTGGTGCCGCCAGACA                                                  
  -----------------------------------------------------------------------------------------------------------

bp, base pair; TLR, toll-like receptor; CXCL-11, C-X-C motif chemokine ligand 11; CXCR-3, C-X-C motif chemokine receptor 3.

###### 

Demographic and Clinical Symptoms of Patients With Irritable Bowel Syndrome and Controls

  Parameters                                                          IBS (n = 47)   Controls (n = 25)   *P*-value
  ------------------------------------------------------------------- -------------- ------------------- -------------------------------------------------
  Age (median \[range\], yr)                                          34 (19--68)    40 (20--68)         0.271[a](#tfn2-jnm-24-628){ref-type="table-fn"}
  Gender (male \[%\])                                                 39 (83%)       22 (88%)            0.573
  Predominant bowel habits (Rome III criteria)                                                           
   IBS-C                                                              20 (43%)       \-                  \-
   IBS-D                                                              20 (43%)       \-                  \-
   IBS-U                                                              7 (14%)        \-                  \-
  Clinical Symptoms                                                                                      
  Visible abdominal distension                                        34 (72%)       0                   \< 0.001
  Abdominal bloating/feeling of abdominal distension \> 1/4 of days   22 (47%)       0                   \< 0.001
  Abdominal pain                                                      35 (74%)       0                   \< 0.001
  Abdominal discomfort                                                47 (100%)      0                   \< 0.001
  Relief of pain/discomfort with bowel movement                       46 (98%)       0                   \< 0.001
  More frequent stool at onset of pain                                13 (28%)       0                   0.004
  Loose stool at onset of pain                                        14 (30%)       0                   0.002
  Urgency                                                             17 (36%)       0                   0.001
  Passage of mucus                                                    35 (74%)       0                   \< 0.001
  Passage of mucus \> 1/4 of defecation                               14 (28%)       0                   0.002
  Feeling of incomplete evacuation                                    45 (96%)       7 (28%)             \< 0.001
  Feeling of incomplete evacuation \> 1/4 of defecation               29 (62%)       0                   \< 0.001
  Straining during defecation                                         27 (57%)       0                   \< 0.001
  Irregular stool form                                                33 (70%)       7 (28%)             0.001
  Irregular stool frequency                                           39 (83%)       9 (36%)             \< 0.001

Non-parametric Mann-Whitney *U* test. Chi-square test was used for all the other categorical data.

IBS, irritable bowel syndrome; IBS-C, constipation-predominant IBS; IBS-D, diarrhea-predominant IBS; IBS-U, unsubtyped IBS; *P* \< 0.05 was significant.

###### 

Relative Expression (2^−ΔCt^) of Toll-like Receptors, Cytokines, and Chemokines Between Patients With Irritable Bowel Syndrome and Controls

  -----------------------------------------------------------------------------------------------------------
  Target gene   Controls (n = 25)\   IBS (n = 47)\      *P*-value[a](#tfn4-jnm-24-628){ref-type="table-fn"}
                median (range)       median (range)     
  ------------- -------------------- ------------------ -----------------------------------------------------
  TLR-2         3.00 (0.0--21.0)     5.00 (0.0--17.0)   0.090

  TLR-4         0.03 (0.0--13.1)     0.24 (0.0--26.6)   0.013

  TLR-5         0.03 (0.0--1.5)      0.77 (0.0--6.5)    \< 0.001

  IL-6          0.10 (0.0--2.8)      0.90 (0.0--5.0)    0.003

  IL-10         1.00 (0.0--8.1)      0.60 (0.0--17.2)   0.546

  CXCL-11       0.10 (0.0--15.4)     2.80 (0.0--98.8)   \< 0.001

  CXCR-3        0.00 (0.0--25.2)     1.80 (0.0--24.8)   \< 0.001
  -----------------------------------------------------------------------------------------------------------

Mann-Whitney *U* tests.

*P*\< 0.005 was considered significant.

IBS, irritable bowel syndrome; TLR, toll-like receptor; CXCL-11, C-X-C motif chemokine ligand 11; CXCR-3, C-X-C motif chemokine receptor 3.

###### 

Relative Expression (2^−ΔCt^) of Toll-like Receptors, Cytokines, and Chemokines, Among Different Subtypes of Patients With Irritable Bowel Syndrome and Controls

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Target gene                                                                                                                               Controls (n = 25)\   IBS-C (n = 20)\    IBS-D (n = 20)\    IBS-U (n = 7)\      *P*-value[a](#tfn7-jnm-24-628){ref-type="table-fn"}
                                                                                                                                            median (range)       median (range)     median (range)     median (range)      
  ----------------------------------------------------------------------------------------------------------------------------------------- -------------------- ------------------ ------------------ ------------------- -----------------------------------------------------
  TLR-4[b](#tfn8-jnm-24-628){ref-type="table-fn"},[c](#tfn9-jnm-24-628){ref-type="table-fn"}                                                0.03 (0.0--13.1)     0.07 (0.0--5.1)    0.40 (0.0--26.6)   0.24 (0.0--2.0)     0.009

  TLR-5[b](#tfn8-jnm-24-628){ref-type="table-fn"},[c](#tfn9-jnm-24-628){ref-type="table-fn"}                                                0.03 (0.0--1.5)      0.45 (0.0--4.9)    2.13 (0.0--6.5)    2.95 (0.4--4.7)     \< 0.001

  IL-6[b](#tfn8-jnm-24-628){ref-type="table-fn"}                                                                                            0.10 (0.0--2.8)      0.45 (0.0--5.0)    1.10 (0.0--2.1)    0.90 (0.0--1.7)     0.016

  IL-10[b](#tfn8-jnm-24-628){ref-type="table-fn"},[c](#tfn9-jnm-24-628){ref-type="table-fn"}                                                1.00 (0.0--8.1)      2.25 (0.0--17.2)   0.05 (0.0--8.8)    0.00 (0.0--3.0)     0.003

  CXCL-11[b](#tfn8-jnm-24-628){ref-type="table-fn"}                                                                                         0.10 (0.0--15.4)     1.35 (0.0--34.7)   3.60 (0.0--57.9)   29.00 (0.4--98.8)   \< 0.001

  CXCR-3[b](#tfn8-jnm-24-628){ref-type="table-fn"},[c](#tfn9-jnm-24-628){ref-type="table-fn"},[d](#tfn10-jnm-24-628){ref-type="table-fn"}   0.00 (0.0--25.2)     0.80 (0.0--8.3)    4.40 (0.0--24.8)   1.00 (0.3--12.0)    \< 0.001
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Kruskal Wallis test with post hoc analysis. *P* \< 0.05 was considered significant.

*P* \< 0.017 between patients with IBS-D and controls.

*P* \< 0.017 between IBS-C and IBS-D.

Bonferroni corrected *P*-value \< 0.017 was considered significant for subgroup analysis.

###### 

Association Between Clinical Symptoms of Irritable Bowel Syndrome and Toll-like Receptors, Cytokines, and Chemokines

  Target genes   More frequent stool at the onset of pain   Loose stool at the onset of pain   Stool \> 3/day   Loose water stool   Lumpy/hard stool                                                                                                                                           
  -------------- ------------------------------------------ ---------------------------------- ---------------- ------------------- ------------------ ------- ------------------ ----------------- ------- ------------------ ----------------- ------- ------------------ ------------------ -------
  TLR-4          0.04 (0.0--2.7)                            0.01 (0.0--1.0)                    0.034            0.02 (0.0--2.7)     0.03 (0.0--1.0)    0.843   0.03 (0.0--2.7)    0.01 (0.0--0.6)   0.018   0.03 (0.0--2.7)    0.01 (0.0--0.6)   0.037   0.01 (0.0--0.6)    0.03 (0.0--2.7)    0.014
  TLR-5          1.46 (0.0--4.8)                            0.71 (0.0--6.5)                    0.849            0.75 (0.0--4.7)     0.77 (0.0--6.5)    0.538   2.41 (0.0--6.5)    0.52 (0.0--4.9)   0.047   1.85 (0.0--6.5)    0.52 (0.0--4.9)   0.049   0.59 (0.0--4.9)    2.41 (0.0--6.5)    0.085
  IL-10          0.00 (0.0--1.2)                            0.17 (0.0--1.7)                    0.051            0.00 (0.0--0.4)     0.14 (0.0--1.7)    0.016   0.00 (0.0--0.9)    0.22 (0.0--1.7)   0.003   0.00 (0.0--0.9)    0.23 (0.0--1.7)   0.002   0.21 (0.0--1.7)    0.00 (0.0--0.9)    0.012
  CXCR-3         4.60 (0.4--19.6)                           1.05 (0.0--24.8)                   0.023            2.40 (0.0--19.6)    1.40 (0.0--24.8)   0.963   3.60 (0.0--24.8)   0.95 (0.0--8.3)   0.011   3.60 (0.0--24.8)   0.85 (0.0--8.3)   0.004   0.95 (0.0--12.0)   4.20 (0.0--24.8)   0.007

P, present; A, absent; TLR, toll-like receptor; CXCR-3, C-X-C motif chemokine receptor 3.

Mann-Whitney *U* test was used to find out the association between clinical symptoms of irritable bowel syndrome and TLRs (4 and 5), cytokines (IL-6 and IL-10), and chemokines (C-X-C motif chemokine ligand 11 \[CXCL-11\] and CXCR-3). *P* \< 0.05 was considered significant.

Data are expressed as median (range).

###### 

Correlation Analysis of Toll-like Receptors, Cytokines, and Chemokines With Duration of Symptoms and Stool Frequency per Week

  Target gene   Duration of symptoms   Stool frequency/wk
  ------------- ---------------------- --------------------
  TLR-2                                
   *r*          −0.262                 −0.132
   *P*-value    0.076                  0.376
  TLR-4                                
   *r*          −0.144                 0.349
   *P*-value    0.333                  0.016
  TLR-5                                
   *r*          −0.154                 0.254
   *P*-value    0.302                  0.085
  IL-6                                 
   *r*          0.038                  0.133
   *P*-value    0.799                  0.374
  IL-10                                
   *r*          0.058                  −0.435
   *P*-value    0.699                  0.002
  CXCL-11                              
   *r*          0.246                  0.129
   *P*-value    0.096                  0.387
  CXCR-3                               
   *r*          0.031                  0.399
   *P*-value    0.835                  0.005

TLR, toll-like receptor; CXCL-11, C-X-C motif chemokine ligand 11; CXCR-3, C-X-C motif chemokine receptor 3.

*r*, Spearman correlation coefficient. *P* \< 0.05 was considered significant.
